Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Gynecol Obstet Invest ; 83(5): 443-454, 2018.
Article in English | MEDLINE | ID: mdl-29227976

ABSTRACT

OBJECTIVE: To investigate whether ulipristal acetate (UPA) treatment modifies the expression of progesterone receptor (PR), its nuclear cofactors steroid receptor coactivator-1 (SRC1) and nuclear corepressor-1 (NCoR1), prosurvival factor B-cell lymphoma 2 (Bcl-2), and Akt in uterine myomas. PATIENTS: Prospective study of 59 women with symptomatic myomas undergoing myomectomy. Forty-two patients were treated preoperatively with UPA; the remaining 17 were not and they served as controls. METHOD: Tissue microarrays were obtained from surgical specimens and immunohistochemistry was performed. Blinded quantification of expression of PR (PR-A vs. PR-B), coactivator SRC1 and corepressor NCoR1, and prosurvival factor Bcl-2, and Akt and evaluation of Akt phosphorylation levels. RESULTS: Compared with the control group, UPA does not alter PR protein levels or expression patterns in myomas, and the PR-A/PR-B ratio was similar, as well as cytoplasmic or nuclear expression of cofactors SRC1 and NCoR1. Bcl-2 was heterogeneously expressed throughout the samples and no significant modification in expression was evidenced. No significant difference was found in Akt expression and phosphorylation between treated and untreated myomas. CONCLUSION: This study did not find any significant change in the expression of the studied factors in myomas after UPA exposure. In conclusion, various theories on myomas cells proposed on the basis of in vitro studies are not supported in vivo.


Subject(s)
Leiomyoma/metabolism , Nuclear Receptor Coactivator 1/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptors, Progesterone/metabolism , Uterine Neoplasms/metabolism , Adult , Case-Control Studies , Co-Repressor Proteins , Female , Humans , Leiomyoma/drug therapy , Leiomyoma/pathology , Norpregnadienes/therapeutic use , Phosphorylation , Prospective Studies , Protein Isoforms , Receptors, Progesterone/therapeutic use , Uterine Neoplasms/drug therapy , Uterine Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...